Literature DB >> 25083258

Opposing conclusions from post hoc analyses of the AFFIRM trial: was propensity score analysis to blame or just an innocent victim?

Richard J Woodman1.   

Abstract

Year:  2014        PMID： 25083258      PMCID： PMC4110877          DOI： 10.1177/2042098613517416

Source DB:  PubMed          Journal:  Ther Adv Drug Saf        ISSN： 2042-0986


× No keyword cloud information.
  10 in total

1.  A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation.

Authors:  Isabelle C Van Gelder; Vincent E Hagens; Hans A Bosker; J Herre Kingma; Otto Kamp; Tsjerk Kingma; Salah A Said; Julius I Darmanata; Alphons J M Timmermans; Jan G P Tijssen; Harry J G M Crijns
Journal:  N Engl J Med       Date:  2002-12-05       Impact factor: 91.245

Review 2.  Evaluating non-randomised intervention studies.

Authors:  J J Deeks; J Dinnes; R D'Amico; A J Sowden; C Sakarovitch; F Song; M Petticrew; D G Altman
Journal:  Health Technol Assess       Date:  2003       Impact factor: 4.014

3.  Propensity scores: from naive enthusiasm to intuitive understanding.

Authors:  Elizabeth Williamson; Ruth Morley; Alan Lucas; James Carpenter
Journal:  Stat Methods Med Res       Date:  2011-01-24       Impact factor: 3.021

4.  Digoxin for patients with atrial fibrillation and heart failure: paradise lost or not?

Authors:  Dirk J van Veldhuisen; Isabelle C Van Gelder; Ali Ahmed; Mihai Gheorghiade
Journal:  Eur Heart J       Date:  2013-01-16       Impact factor: 29.983

5.  When 'digoxin use' is not the same as 'digoxin use': lessons from the AFFIRM trial.

Authors:  Sabina A Murphy
Journal:  Eur Heart J       Date:  2013-04-16       Impact factor: 29.983

6.  Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial.

Authors:  Ali Ahmed; Michael W Rich; Thomas E Love; Donald M Lloyd-Jones; Inmaculada B Aban; Wilson S Colucci; Kirkwood F Adams; Mihai Gheorghiade
Journal:  Eur Heart J       Date:  2005-12-08       Impact factor: 29.983

7.  Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study.

Authors:  Scott D Corley; Andrew E Epstein; John P DiMarco; Michael J Domanski; Nancy Geller; H Leon Greene; Richard A Josephson; Joyce C Kellen; Richard C Klein; Andrew D Krahn; Mary Mickel; L Brent Mitchell; Joy Dalquist Nelson; Yves Rosenberg; Eleanor Schron; Lynn Shemanski; Albert L Waldo; D George Wyse
Journal:  Circulation       Date:  2004-03-08       Impact factor: 29.690

8.  Lack of evidence of increased mortality among patients with atrial fibrillation taking digoxin: findings from post hoc propensity-matched analysis of the AFFIRM trial.

Authors:  Mihai Gheorghiade; Gregg C Fonarow; Dirk J van Veldhuisen; John G F Cleland; Javed Butler; Andrew E Epstein; Kanan Patel; Inmaculada B Aban; Wilbert S Aronow; Stefan D Anker; Ali Ahmed
Journal:  Eur Heart J       Date:  2013-04-16       Impact factor: 29.983

9.  A most stubborn bias: no adjustment method fully resolves confounding by indication in observational studies.

Authors:  Jaclyn L F Bosco; Rebecca A Silliman; Soe Soe Thwin; Ann M Geiger; Diana S M Buist; Marianne N Prout; Marianne Ulcickas Yood; Reina Haque; Feifei Wei; Timothy L Lash
Journal:  J Clin Epidemiol       Date:  2009-05-19       Impact factor: 6.437

10.  Increased mortality among patients taking digoxin--analysis from the AFFIRM study.

Authors:  Matthew G Whitbeck; Richard J Charnigo; Paul Khairy; Khaled Ziada; Alison L Bailey; Milagros M Zegarra; Jignesh Shah; Gustavo Morales; Tracy Macaulay; Vincent L Sorrell; Charles L Campbell; John Gurley; Paul Anaya; Hafez Nasr; Rong Bai; Luigi Di Biase; David C Booth; Guillaume Jondeau; Andrea Natale; Denis Roy; Susan Smyth; David J Moliterno; Claude S Elayi
Journal:  Eur Heart J       Date:  2012-11-27       Impact factor: 29.983
  10 in total
  2 in total

Review 1.  Rate control strategies for atrial fibrillation.

Authors:  Muath Alobaida; Abdullah Alrumayh
Journal:  Ann Med       Date:  2021-12       Impact factor: 4.709

2.  Laquinimod efficacy in relapsing-remitting multiple sclerosis: how to understand why and if studies disagree.

Authors:  Gary R Cutter; Volker Knappertz; Nissim Sasson; David Ladkani
Journal:  BMC Neurol       Date:  2016-09-17       Impact factor: 2.474
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.